Summary of cardiovascular effects, receptor binding affinity in rat brain preparations and neurobehavioral effects in mice for selected cannabinoid compounds; compounds listed in descending rank order of potency (top to bottom)
| Compound | binding Ki | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pressor | Hypotension | Bradycardia | CB1 | CB2 | Hypothermia | Antinociception | Ring Immobility | Hypoactivity | |||||||||
| ED50 (mg/kg, i.v.) | ED50 (mg/kg, i.v.) | Emax (mm Hg) | ED50 (mg/kg, i.v.) | Emax(bpm) | (nM) | ED50 (mg/kg, i.v.) | ED50 (mg/kg, i.v.) | ED50 (mg/kg, i.v.) | ED50 (mg/kg, i.v.) | ||||||||
| HU-210 | NA | 0.002 | −82 | 0.09 | −217 | 0.731-a | 0.221-b | 0.021-c | 0.0091-c | 0.021-c | 0.0041-c | ||||||
| CP-55940 | NA | 0.01 | −83 | 0.12 | −218 | 0.581-b | 0.691-b | 0.31-d | 0.091-d | 0.41-d | 0.041-d | ||||||
| WIN-55212-2 | NA | 0.1 | −84 | 0.29 | −267 | 1.821-b | 0.281-b | 121-e | 0.41-e | 1.11-e | 0.11-e | ||||||
| Δ9-THC | 2.47 | 0.27 | −62 | 0.62 | −140 | 40.71-a | 36.41-b | 1.41-f | 1.41-f | 1.51-f | 1.01-f | ||||||
| Anandamide | 1.57 | 2.54 | −46 | 2.54 | −43 | 1011-g | 3711-b | 26.51-g | 6.21-g | 19.11-g | 17.91-g | ||||||
| JWH-015 | NA | 10.1 | −78 | 14.3 | −170 | 3361-h | 13.81-b | ND | 23.91-i | ND | ND | ||||||
| HU-211 | NA | NA | NA | NA | NA | 1,9901-a | >10,0001-b | >301-c | >301-c | >301-c | >301-c | ||||||
| Palmitoylethanolamine | NA | >20 | NA | NA | NA | >1,0001-j | >10,0001-b | ND | ND | ND | ND | ||||||
| O-522 | >30 | >30 | NA | >30 | NA | >10,0001-i | ND | >601-i | >301-i | >601-i | >301-i | ||||||
| O-502 | >30 | >30 | NA | >30 | NA | >10,0001-i | ND | >601-i | >301-i | >601-i | >301-i | ||||||
NA, Not applicable; ND, not done.
↵1-a Compton et al., 1993.
↵1-b Showalter et al., 1996.
↵1-c Little et al., 1989.
↵1-d Little et al., 1988.
↵1-e Compton et al., 1992b.
↵1-f Compton et al., 1992a.
↵1-g Smith et al., 1994.
↵1-h Kuster et al., 1993.
↵1-i Compton et al., unpublished data.
↵1-j Devane et al., 1992.